Jean-Christophe Delumeau, a member of the Scientific Board of the International Society of Pharmacovigilance (ISoP), graduated in medicine and neuropharmacology from universities of Rennes and Sorbonne (Paris).

After medical residency, he completed a research program in intracellular signalling at the National Institute of Medical Research (Inserm, France), then moved to clinical research in healthcare companies based in Basel, Paris, and Tokyo where he conducted multinational trials in neurodegenerative diseases and cerebrovascular disorders.

From 2001 until June 2020, he exerted the responsibilities of regional pharmacovigilance leader at Bayer in Japan, China, and Singapore until his appointment as head of pharmacovigilance policy strategy with a global scope. On July 1st, 2022, Jean-Christophe Delumeau, was appointed as a board director of the Institute of Pharmacovigilance, the NGO developing the Global Pharmacovigilance Professional Certification in collaboration with ISoP.